discs large MAGUK scaffold protein 2Genealiases: PPP1R58 · PSD-93 · PSD93 · chapsyn-110
Q-omics provides the consensus-scored DLG2 profile across patient tissues and cancer cell-line models. DLG2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DLG2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DLG2 RNA expression shows 25,617 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where DLG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLG2 survival associations across molecular data types. DLG2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLG2 RNA expression–survival associations across cancer types. High DLG2 expression shows unfavorable associations in LUSC, but favorable associations in KIRC, UCS, ACC, MESO and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DLG2 RNA expression.
This table summarizes DLG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DLG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLG2 shows lower tumor expression in HNSC, KIRC, THCA, BLCA, UCEC and KIRP. The HNSC box plot shows higher DLG2 RNA expression in normal versus tumor tissue (log2 FC = −0.905, t-test p < 0.001).
This table shows molecular features associated with DLG2 in patient tissues and cancer cell lines. In patient samples, DLG2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DLG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
